Gadolinium-based mostly distinction agents (GBCAs) are broadly used in magnetic resonance imaging (MRI) to improve the visibility of blood vessels, tumors, inflammation, as well as other interior constructions. Although typically deemed Protected, issues about GBCA toxicity have emerged in the last two decades—particularly in sufferers with impai